With 5 year clinical data to be presented at a conference in april, the market is clearly appreciating the steady progress being delivered by CEO Pål Ryfors and his team.
The stock has established a very solid uptrend that is consolidating well above the 50 day moving average, and seems like it could very well do a breakout above the 3 SEK level.
-----------------------------------
Episealer®: Clinical results with 5-years’ follow-up data to be presented at the 3rd World Arthroplasty Congress
MON, FEB 15, 2021 08:00 CET
Episurf Medical (Nasdaq: EPIS B) today announces that the scientific report "Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years” by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, has been accepted for presentation at the 3rd World Arthroplasty Congress. The congress is arranged as a digital meeting on April 22-24, 2021. The presentation will be included in the ePosters Knee Session and focuses on clinical results from the use of the Episealer® knee implant.
“This is a great milestone for us as a company. For the first time ever, clinical results with 5-years’ follow-up of Episealer® patients are included in the scientific program at a major clinical congress. The investigator has informed us that the results are highly promising. Being able to demonstrate successful 5-years’ data is a critical milestone for any medtech company, but absolutely nothing one should take for granted. As previously communicated, another Episealer® knee study with promising 5 years’ follow-up data has been submitted for publication. I cannot emphasize enough the importance of all of this,” says Pål Ryfors, CEO Episurf Medical.
The stock has established a very solid uptrend that is consolidating well above the 50 day moving average, and seems like it could very well do a breakout above the 3 SEK level.
-----------------------------------
Episealer®: Clinical results with 5-years’ follow-up data to be presented at the 3rd World Arthroplasty Congress
MON, FEB 15, 2021 08:00 CET
Episurf Medical (Nasdaq: EPIS B) today announces that the scientific report "Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years” by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, has been accepted for presentation at the 3rd World Arthroplasty Congress. The congress is arranged as a digital meeting on April 22-24, 2021. The presentation will be included in the ePosters Knee Session and focuses on clinical results from the use of the Episealer® knee implant.
“This is a great milestone for us as a company. For the first time ever, clinical results with 5-years’ follow-up of Episealer® patients are included in the scientific program at a major clinical congress. The investigator has informed us that the results are highly promising. Being able to demonstrate successful 5-years’ data is a critical milestone for any medtech company, but absolutely nothing one should take for granted. As previously communicated, another Episealer® knee study with promising 5 years’ follow-up data has been submitted for publication. I cannot emphasize enough the importance of all of this,” says Pål Ryfors, CEO Episurf Medical.
